Exchange: NASDAQ·Updated 11:23 AM EDT
News
all
press releases
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -15.39% and -31.82%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +54.55% and +149.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
United Therapeutics (UTHR) Q2 Earnings Surpass Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of +6.60% and -2.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Guardian Pharmacy (GRDN) Surges 8.8%: Is This an Indication of Further Gains?
Guardian Pharmacy (GRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Oversold Conditions For Mediwound (MDWD)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
MediWound (MDWD) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
MediWound Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +64.79% and -56.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +20.00% and -91.28%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +36.67% and -53.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.